Research programme: diabetes/obesity therapy - Roche/Merck

Drug Profile

Research programme: diabetes/obesity therapy - Roche/Merck

Latest Information Update: 29 Aug 2011

Price : $50

At a glance

  • Originator Marcadia Biotech
  • Developer Roche
  • Class Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Diabetes mellitus; Obesity

Most Recent Events

  • 29 Aug 2011 No development reported - Preclinical for Obesity in USA (Parenteral)
  • 29 Aug 2011 No development reported - Preclinical for Diabetes mellitus in USA (Parenteral)
  • 30 Dec 2010 Marcadia Biotech has been acquired and merged into Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top